Effect of unilateral amygdalotomy and hypothalamotomy in patients with refractory aggressiveness

Luis García-Muñoz 1,2, Ofir Picazo-Picazo 3, José D. Carrillo-Ruíz 2,4, Jesús Favila-Bojórquez 5,6, Fernando Corona-García 7, Miguel Ángel Meza-Bautista 8 and Fiacro Jiménez-Ponce 9*

1Department of Neurology and Neurosurgery, Hospital General de México “Dr. Eduardo Liceaga”; 2Department of Neurosurgery and Neurology, Specialty Hospital, Centro Médico Nacional Siglo XXI, IMSS, Ciudad de México; 3Higher School of Medicine, Instituto Politécnico Nacional, Ciudad de México; 4Neurosciences Coordination, Universidad Anáhuac, Ciudad de México; 5Department of Psychiatry, Specialty Hospital, Centro Médico Nacional Siglo XXI, IMSS, Ciudad de México; 6Mental Hygiene, Secretaría de Salud, Ciudad de México; 7Hospitalization Service, Hospital Psiquiátrico Fray Bernardino Álvarez, Secretaría de Salud, Ciudad de México; 8Department of Neurosurgery, Regional Hospital 110, IMSS, Guadalajara, Jalisco; 9Sub-directorate of Hospital Regulation and Care, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, City of Mexico, Mexico

Abstract

Background: Neurosurgical treatment, although controversial, is considered a useful resource in the treatment of chronic psychiatric diseases such as refractory aggressiveness. Objective: To evaluate the clinical results and side effects of posteromedial hypothalamotomy associated with amygdalotomy in patients with refractory aggressiveness. Method: A clinical trial was conducted in patients with chronic aggressiveness and refractory to pharmacological treatment. A central amygdalotomy associated with posteromedial hypothalamotomy was performed using thermo-coagulation by radiofrequency. The degree of aggressiveness was quantified by the Yudofsky’s global scale of aggression. Postoperative changes in aggressive behavior continued to be evaluated every 6 months for at least 36 months. Results: A statistically significant change in aggressive behavior was observed during 36 months of follow-up. The collateral effects of the association of both procedures are described, the most frequent being drowsiness and some cases of reduction in sexual behavior. Conclusion: Symmetric and simultaneous unilateral lesions of the central nucleus of the amygdala and the posteromedial hypothalamus contralateral to motor dominance give the same clinical effect in the reduction of the pathological aggression that the bilateral lesions.


Background

“Normal” aggressive behavior has very specific objectives: to maintain the individual’s physical integrity, predation for subsistence purposes, vital space or territory preservation and perpetuation of the species. These functions are perfectly summarized in the term expressed by Walter Canon1, “fight or flight”. Human aggressiveness shows a common pattern of behaviors similar to other animal species and is only activated in the presence of a threatening stimulus. This innate behavior is associated with the limbic system. The first description of the existence of an “emotional brain” was made by Christfried Jakob2 in 1907-1908, laying the groundwork for subsequent contributions by James W. Papez in 1932 and Paul D. MacLean3. These concepts culminated in the integration of the limbic system and gave a better insight, between physiology and anatomy, in the generation and control of behavioral and emotional patterns. On the other hand, “unnatural or pathological” aggressiveness is an exaggerated behavior that occurs disproportionately in the presence of a stimulus that normally would not imply danger. This symptom is present with certain frequency in some neurological and/or psychiatric conditions.
According to Yudofsky, pathological aggressive behavior is stereotyped and can be manifested by emitting noises or foul language, causing damage to objects or animals, infringing physical injuries to other people (hetero-aggressiveness) or against themselves (auto-aggressiveness). Yudofsky believes that aggressive behavior in patients is related to neurological or psychiatric damage, and therefore it should be considered as a “neuro-aggressive disorder”. The treatment of this disorder involves the use of neuroleptic drugs, benzodiazepines, anticonvulsants, antidepressants, beta-blockers or mood modulators. Refractory neuro-aggressive disorder is a problem not only because of the social risk it implies, but also because of the high costs of drug treatment, frequent hospitalizations required for the control of crises and because of the high percentage of improvement of the results obtained by CA alone. On the other hand, already in 2012, the combination of cingulotomy and anterior bilateral capsulotomy was proposed for the control of refractory aggressive behavior.

As a substitute therapeutic alternative for radiofrequency injury, in 2013, Franzolini treated patients with refractory aggressiveness using deep brain electrical stimulation in both posteromedial hypothalamuses (PMH). However, the procedure is still under investigation.

Our group has already published the preliminary historical results of a case series where symmetrical unilateral CA and PMH lesions contralateral to manual dominance decreased refractory aggressive behavior in neuro-aggressive disorder. Thus, the main purposes of this clinical trial were to assess the clinical results and side effects of PMH lesions associated with CA, unilaterally, symmetrically or asymmetrically, ipsilaterally or contralaterally to manual dominance.

Method

Between 2012 and 2017, patients diagnosed with refractory aggression were treated. All patients had been referred by psychiatrists from different institutions requesting neurosurgical management for the treatment of refractory aggression. All cases were submitted to a committee composed of two psychiatrists and two functional neurosurgeons. The following requirements were established as inclusion criteria: a)
clinical symptoms chronicity, with a history of at least 5 years; b) difficulty in controlling aggressive behavior (on a correct pharmacological treatment, for at least two years and with good therapeutic adherence) or, that in spite of an adequate clinical response, had adverse effects to the used medication such as liver dysfunction, diabetes mellitus or metabolic syndrome, and c) neuroimaging studies ruling out neoplastic, vascular, infectious, demyelinating or parasitic disease. Patients who were treated with ECT were not rejected for surgical management. In all cases, blood dyscrasias were ruled out, cardiovascular risk was determined when necessary, and brain magnetic resonance was performed, both to rule out aggregate diseases and for stereotactic surgical planning. Informed consent was requested to perform CA and PMH with radiofrequency thermo-coagulation (RFTC), which was obtained directly when patients had autonomy and were capable to decide or through the parents or legal guardians. The Explicit Aggressiveness Scale proposed by Yudofsky, or better known as Overt Aggression Scale (OAS), which is a measuring instrument validated in Mexico\(^\text{18}\), was used to measure and determine aggressive behavior. The scale includes four chapters, which consist of verbal aggressiveness, aggressiveness against objects, auto-aggressiveness and hetero-aggressiveness. Each chapter has a maximum value of 4 points and total score is 16. The determination of motor dominance was made using the Edinburgh scale\(^\text{20}\).

Due to the nature of the condition, patients were hospitalized one day prior to the surgical procedure, maintaining their pharmacological treatment as indicated by the psychiatrist. The surgical procedure was performed under general anesthesia, and thus was the stereotactic framework placed and computed cranial tomography performed for the planning of anatomical sites. The Zamorano-Dujovny (Z-D) stereotaxic system (Fischer, Leibinger, Germany) or the Leksell framework (Elekta AB, Sweden) were used to locate CA and PMH. To locate the PMH, the stereotactic coordinates reported by Sano were taken as a reference: \(x = 2.0\) mm lateral to the wall of the third ventricle, \(y = \text{commissural midpoint}\) and \(z = 2.0\) mm below the intercomisural line. The \(z\) coordinate was scanned from 4 mm above the site to begin electrical stimulation prior to the lesion\(^\text{11}\). For the location of CA, Andy and Stephan\(^\text{18}\) coordinates of were taken as reference, which were adjusted with the Talairach\(^\text{21}\) and Schaltenbrand and Warhen Stereotactic Brain Atlases: \(x = 20-26 (24)\) mm for amygdala lateral component, \(y = 3\) to 5 \((2\) to 4) mm in front of the temporal horn and \(z = 7\) mm above the floor of the temporal ventricle (or 15 mm below the intercomisural line). The Stereoplan\(^\text{R}\) (Fischer, Leibinger, Germany), Praezis\(^\text{R}\) (Leibinger, Germany) or Framelink\(^\text{R}\) (Medtronic, USA) programs were used to calculate the coordinates in patient images. To address the nuclei, a coronal bur hole was placed 3 cm lateral to the midline.

In view the functional complications reported in the medical literature when bilateral lesions on the same nucleus are performed at the same time, both for the amygdaloid complex (AC) and postero medial hypothalamus, we combined the nuclei, either simultaneously unilaterally for both or bilaterally at different times.

The AC lesion was performed with a bipolar electrode of 0.5 mm in diameter (Fischer, Leibinger, Germany), at 80° C for 90 seconds. For the hypothalamic lesion, a 0.3-mm diameter bipolar electrode (Fischer, Leibinger, Germany) was used, at 80° C for 60 seconds, using a RFTC lesion generator (N-50, Fischer, Leibinger, Germany). Only for PMH were electrical stimulation tests performed using voltages between 1.0 and 8.0 V, 500-1000 µs and 100 Hz continuously until a sympathetic response was obtained. Correct location of the electrode within the PMH caused ipsilateral mydriasis, arterial hypertension and tachycardia.

When both CA and PMH lesion was performed with RFTC at the same surgical time, the procedure was referred to as simultaneous. When the lesions of both nuclei were made in the same cerebral hemisphere, it was called symmetric. When the treated nuclei were not in the same cerebral hemisphere, for example, right CA and left PMH or vice versa, the procedure was called asymmetric. If only one nucleus was operated, CA or PMH, it was referred to as unilateral. In this series, no simultaneous bilateral RFTC lesion was performed, either CA or PMH, in order to avoid functional damage due to bilateral lesion.

Postoperative changes in aggressive behavior continued to be assessed every 6 months for at least 36 months with the OAS scale.

Results

The study included 12 patients, 11 men and 1 woman. Mean age was 31.8 ± 11.48 standard deviation (SD). Refractory pathological aggressiveness was present in eight cases with mental retardation (MR) and, in this group, four subjects did not develop language, two related to Asperger’s syndrome, one to
autism and the other to epilepsy. Two subjects were related to schizophrenia, one to posttraumatic syndrome (who also developed obsessive-compulsive disorder) and another to borderline personality disorder. All patients showed an extreme aggressiveness pattern of 16 points, which is the highest possible score according to Yodosfsky’s global scale. Four cases showed hetero-aggressiveness and eight the combined form (hetero-aggressiveness plus auto-aggressiveness). Five male patients showed increased and uninhibited sexual behavior, manifested with public masturbation and one case was also accompanied by sexual harassment. In four cases, sexual behavior was not reported and in three it was referred to as “normal”. Nine patients were right-handed. All patients received at least one neuroleptic drug (quetiapine, haloperidol, ziprasidone, olanzapine, risperidone, chlorpromazine and clozapine) associated with an antiepileptic drug (carbamazepine, Mg valproate, clonazepam, levetiracetam and lorazepam). In one case, methylenophenidate was used. Each patient received between three and five drugs to reduce aggressive behavior and in all cases except one, adverse effects occurred, with the most common being extrapyramidal phenomena (torsion dystonia) in six cases, diabetes mellitus in four patients, metabolic syndrome with thrombocytopenia and gynecomastia in one and another with drowsiness and sialorrhea. Nine patients received ECT prior to surgery (Table 1).

In the first five cases, unilateral RFTC of both AC and PMH was randomly selected simultaneously but not symmetrically. These first treated cases had to be re-operated in less than three months due to aggressive behavior relapse. With the second surgical procedure, it was observed that when completing nuclei bilaterality, whether outside the amygdala or the posteromedial hypothalamus, the therapeutic effect was achieved as long as the PMH and AC lesions of the coincided contralateral to manual dominance. The observations and analysis of these first five cases reaffirmed the data of the previous study on PMH and AC dominance. In the seven subsequent patients, site allocation was performed based on motor dominance (Table 2).

<table>
<thead>
<tr>
<th>Case</th>
<th>Gender</th>
<th>Age</th>
<th>Comorbidity</th>
<th>Language</th>
<th>Sexuality</th>
<th>Type</th>
<th>Dominance</th>
<th>Medication</th>
<th>Adverse Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>LSF</td>
<td>M</td>
<td>28</td>
<td>MR</td>
<td>Yes</td>
<td>Hyper</td>
<td>Hetero</td>
<td>Right</td>
<td>QTP, HPD, ZSD, CBZ</td>
<td>Torsion dystonia</td>
</tr>
<tr>
<td>ASF</td>
<td>M</td>
<td>22</td>
<td>MR + Asperger</td>
<td>No</td>
<td>Hyper</td>
<td>Hetero/Auto</td>
<td>Left</td>
<td>OLZ, CBZ, VPM, CLZ</td>
<td>Torsion dystonia</td>
</tr>
<tr>
<td>AAJ</td>
<td>M</td>
<td>23</td>
<td>MR + Autism</td>
<td>No</td>
<td>NR</td>
<td>Hetero/Auto</td>
<td>Right</td>
<td>QTP, HPD, ZSD, CBZ</td>
<td>Diabetes mellitus</td>
</tr>
<tr>
<td>RCA</td>
<td>M</td>
<td>28</td>
<td>MR</td>
<td>Yes</td>
<td>Hyper</td>
<td>Hetero</td>
<td>Right</td>
<td>VPM, LTC, CLZ, QTP, LMZ</td>
<td>Diabetes mellitus</td>
</tr>
<tr>
<td>NiHR</td>
<td>M</td>
<td>33</td>
<td>MR</td>
<td>No</td>
<td>Hyper</td>
<td>Hetero/Auto</td>
<td>Left</td>
<td>HPD, LTC, PDM, CLZ, LMZ</td>
<td>Diabetes mellitus, Thrombocytopenia, Gynecomastia, Metabolic syndrome</td>
</tr>
<tr>
<td>GBMA</td>
<td>M</td>
<td>20</td>
<td>MR</td>
<td>Yes</td>
<td>NR</td>
<td>Hetero</td>
<td>Left</td>
<td>MFD, ZSD, HPD, RPD, VPM</td>
<td>Torsion dystonia, Diabetes mellitus</td>
</tr>
<tr>
<td>BRLM</td>
<td>M</td>
<td>32</td>
<td>OCD, TBI</td>
<td>Yes</td>
<td>Hyper</td>
<td>Hetero</td>
<td>Right</td>
<td>VPM, CBZ, QTP</td>
<td>Somnolence + Sialorrhea</td>
</tr>
<tr>
<td>ACC</td>
<td>M</td>
<td>22</td>
<td>BPD</td>
<td>Yes</td>
<td>Normal</td>
<td>Hetero/Auto</td>
<td>Right</td>
<td>QTP, VPM, CLZ</td>
<td>None</td>
</tr>
<tr>
<td>RLM</td>
<td>F</td>
<td>32</td>
<td>MR + Epilepsy</td>
<td>Yes</td>
<td>Normal</td>
<td>Hetero/Auto</td>
<td>Right</td>
<td>VPM, LTC, PRM, QTP</td>
<td>Thrombocytopenia</td>
</tr>
<tr>
<td>CLC</td>
<td>M</td>
<td>48</td>
<td>SCZ</td>
<td>Yes</td>
<td>NR</td>
<td>Hetero/Auto</td>
<td>Right</td>
<td>HPD, QTP, VPM</td>
<td>Torsion dystonia</td>
</tr>
<tr>
<td>EMZE</td>
<td>M</td>
<td>59</td>
<td>SCZ</td>
<td>Yes</td>
<td>Normal</td>
<td>Hetero/Auto</td>
<td>Right</td>
<td>HPD, QTP, CBZ</td>
<td>Torsion dystonia</td>
</tr>
<tr>
<td>GMA</td>
<td>M</td>
<td>35</td>
<td>MR + Autism</td>
<td>No</td>
<td>Normal</td>
<td>Hetero/Auto</td>
<td>Right</td>
<td>CPMZ, CZP, LZP, VPM</td>
<td>Torsion dystonia</td>
</tr>
</tbody>
</table>

OCD: obsessive compulsive disorder; MR: mental retardation; TBI: traumatic brain injury; SCZ: schizophrenia; QTP: quetiapine; HPD: haloperidol; ZSD: ziprasidone; CBZ: carbamazepine; OLZ: olanzapine; VPA: mg valproate; CLZ: clonazepam; LTC: levetiracetam; L2P: lorazepam; MFD: methylphenidate; RPD: risperidone; PRD: primidone; CPMZ: chlorpromazine; CZP: clozapine.
For the purpose of this report, follow-up was carried out at 6, 12, 18, 24, 30 and 36 months. The first nine cases have already reached 60 months of follow-up.

Table 3 shows the changes in the OAS-obtained values. Applying the non-parametric Wilcoxon rank test to the measurements obtained at baseline in comparison with each follow-up, a statistically significant change was observed, although the 36-month follow-up was not completed in the last three cases.

Figure 1 shows the typical magnetic resonance images of the immediate postoperative period after the CA and PHM procedures. The main side effects and changes in sexual behavior were highly important, since, in all cases, there was nearly a disappearance of sexual interest. No patient required intensive care management after surgery (Table 4).

Discussion

The results obtained in this work show a statistically significant change in the aggressive behavior as assessed by the OAS scores. There was median a decrease of between 13 and 14 points over 36 months of follow-up (p between 0.002 and 0.007) (Table 3). The main purpose of this work was to identify which combination of radiofrequency lesions directed to the center of the amygdaloid nucleus or posteromedial hypothalamus lesion could be more effective in producing a clinical change. The assessment of the first five cases where the reappearance of neuro-aggressive syndrome symptoms almost immediately guided this group of researchers to consider the combination
of symmetric amygdalotomy and hypothalamotomy contralateral to manual dominance as the first surgical option. The previous work of this same group had glimpsed this possibility. Thus, the main contribution of this work has been the measurement of the changes obtained by CA and PMH RFTC using a standardized instrument in patients followed for 36 months, as well as to describe that aggressiveness can have a hemispheric laterality shared with manual dominance.

Other previous works, such as those reported by this same group in 2012, had already found that multiple lesion of frontal projections to basal nucleus structures can decrease aggressive behavior at the expense of diminishing executive functions. The reports of all previous authors who have already informed on the effectiveness of the CA and PMH procedure have not been followed for so long and have not used an instrument validated in Mexico.

However, this work is still a preliminary study that seeks a surgical option in cases of patients with refractory aggression that have not improved in their clinical, family and social conditions with conventional treatments. The main limitations of this work correspond to those inherent to a self-controlled pilot study and are the small number of cases included and the lack of a control group. However, except for Ramamurti studies, most published articles are on case series with a small number of enrolled patients and no control group, which is not possible because a surgical procedure of this type cannot be compared with a randomly assigned surgery simulation.

Although a self-controlled study was conducted and a non-parametric statistical test (Wilcoxon rank test) was applied, it is necessary to extend the experience in other groups of researchers dedicated to this field of medicine.

Left-handed ASF patient improved his clinical conditions by completing the right hypothalamus RFTC, considering that he had already undergone a left amygdala and hypothalamus lesion. In this particular case, the combination of the two hypothalami and the non-dominant amygdala improved the patient’s conditions and drive us to think that the assessment of dominance might be difficult sometimes or that multiple lesions, as in the case of bilateral capsulotomy and cingulotomy, are also effective.

The mechanism of action of these surgical procedures has already been discussed in works of the original authors, who have referred to the interruption of the limbic system as the main explanation of the mechanism of action of these procedures.

This group of researchers believes that it would be interesting to explore the effects of these same
cerebral nuclei with deep brain electrical stimulation, where randomization and blinding could be used. When implanting a patient with brain electrodes, and after informed consent, patients can be randomly selected to be under stimulation or without it, and since stimulation is silent in terms of its local action it is also relatively easy for a double or triple blind study to be designed. However, no such clinical trial has been carried out.

It is clearly necessary that another group of researchers consider replicating the observations on aggressive behavior hemispheric dominance. Left dominance of language and of certain executive functions might guide on the possibility that aggressive behavior might not only be an instinctive activity but rather a motor activity planned and executed to achieve a specific objective, such as directing aggression towards the attainment of territory, of satisfiers or hierarchical level.

It would be important assessing the genetic, hormonal and epigenetic conditions of patients with a neuro-aggressive syndrome; strikingly, in most case series reports of neurosurgically-treated patients, the study subjects are males. Finally, the possibility of performing less invasive procedures such as radiosurgery or deep brain stimulation is so far a pending chapter that is limited by the feasibility of obtaining neuromodulation equipment.

Conclusions

This study concludes that symmetric and simultaneous RFTC-produced unilateral lesions of the central nucleus of the amygdala and postero medial hypothalamus contralateral to motor dominance produce the same clinical effect on reducing pathological aggressiveness than bilateral lesions.

References